Double antibiotic attack: could a combo therapy beat strep in the blood?

NCT ID NCT07240077

Disease control Sponsor: Mahidol University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study compares standard beta-lactam antibiotics alone versus beta-lactam plus levofloxacin in adults with streptococcal bacteremia (bacteria in the blood). 165 participants will be randomly assigned to receive either the combination or monotherapy. The goal is to see if adding levofloxacin reduces complications like persistent infection, death, or spread of infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: levofloxacin (antibiotic) added to beta-lactam antibiotics
What this could lead to: If adding levofloxacin works, it could become a new standard treatment for streptococcal bloodstream infections, reducing complications and deaths.
What could go wrong: This is a relatively small, early-stage trial (165 participants) and may not show a clear benefit. Adding levofloxacin also carries risks like antibiotic resistance and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 165 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults age\>18 years 2. Blood culture positive for Streptococcus (\<72 hours before enrollment) * at least 1 bottle of S. pyogenes, S. agalactiae, S. pneumoniae, S. suis * at least 2 bottle of other Streptococci 3. Receiving or having plan of receiving beta-lactam therapy Exclusion Criteria: 1. Known allergy to beta-lactam or fluroquinolone antibiotics 2. Pregnancy or lactating mother 3. EKG with QT prolongation 4. Diagnosis of infective endocarditis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacteremia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis streptococcal infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacteremia Streptococcus infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

4 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Double antibiotic attack: could a combo therapy beat strep in the blood?

What the study statuses mean